Aptus Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.7M | Buy |
142,030
+7,311
| +5% | +$1.57M | 0.24% | 83 |
|
|
2026
Q1 | $29.3M | Sell |
134,719
-2,786
| -2% | -$618K | 0.23% | 87 |
|
|
2025
Q4 | $31.4M | Buy |
137,505
+2,358
| +2% | +$537K | 0.23% | 88 |
|
|
2025
Q3 | $31.3M | Sell |
135,147
-1,298
| -1% | -$264K | 0.23% | 84 |
|
|
2025
Q2 | $25.3M | Buy |
136,445
+13,171
| +11% | +$2.45M | 0.21% | 102 |
|
|
2025
Q1 | $25.8M | Buy |
123,274
+9,959
| +9% | +$1.94M | 0.27% | 81 |
|
|
2024
Q4 | $20.1M | Buy |
113,315
+29,972
| +36% | +$5.51M | 0.21% | 104 |
|
|
2024
Q3 | $16.5M | Buy |
83,343
+14,457
| +21% | +$2.7M | 0.25% | 97 |
|
|
2024
Q2 | $11.8M | Buy |
68,886
+13,887
| +25% | +$2.3M | 0.21% | 100 |
|
|
2024
Q1 | $10M | Buy |
54,999
+4,673
| +9% | +$805K | 0.19% | 104 |
|
|
2023
Q4 | $7.8M | Sell |
50,326
-4,844
| -9% | -$706K | 0.21% | 100 |
|
|
2023
Q3 | $8.22M | Buy |
55,170
+874
| +2% | +$128K | 0.22% | 91 |
|
|
2023
Q2 | $7.32M | Sell |
54,296
-12,873
| -19% | -$1.89M | 0.18% | 112 |
|
|
2023
Q1 | $10.7M | Buy |
67,169
+3,705
| +6% | +$566K | 0.29% | 73 |
|
|
2022
Q4 | $10.3M | Buy |
63,464
+7,903
| +14% | +$1.21M | 0.31% | 66 |
|
|
2022
Q3 | $7.46M | Sell |
55,561
-17,458
| -24% | -$2.51M | 0.18% | 76 |
|
|
2022
Q2 | $11.2M | Buy |
73,019
+26,921
| +58% | +$4.11M | 0.29% | 50 |
|
|
2022
Q1 | $7.47M | Sell |
46,098
-5,295
| -10% | -$769K | 0.19% | 79 |
|
|
2021
Q4 | $6.96M | Buy |
51,393
+7,113
| +16% | +$840K | 0.21% | 67 |
|
|
2021
Q3 | $4.78M | Buy |
44,280
+8,773
| +25% | +$1M | 0.12% | 88 |
|
|
2021
Q2 | $4M | Buy |
35,507
+4,494
| +14% | +$506K | 0.12% | 93 |
|
|
2021
Q1 | $3.36M | Buy |
31,013
+814
| +3% | +$87.1K | 0.12% | 94 |
|
|
2020
Q4 | $3.24M | Sell |
30,199
-263
| -0.9% | -$25.3K | 0.15% | 92 |
|
|
2020
Q3 | $2.67M | Buy |
30,462
+1,165
| +4% | +$110K | 0.14% | 91 |
|
|
2020
Q2 | $2.88M | Buy |
29,297
+1,608
| +6% | +$142K | 0.18% | 78 |
|
|
2020
Q1 | $2.11M | Sell |
27,689
-28,602
| -51% | -$2.44M | 0.18% | 93 |
|
|
2019
Q4 | $4.98M | Buy |
56,291
+8,022
| +17% | +$666K | 0.35% | 49 |
|
|
2019
Q3 | $3.65M | Buy |
48,269
+28,501
| +144% | +$1.95M | 0.2% | 49 |
|
|
2019
Q2 | $1.44M | Buy |
19,768
+306
| +2% | +$24.1K | 0.2% | 94 |
|
|
2019
Q1 | $1.57M | Buy |
19,462
+1,250
| +7% | +$102K | 0.27% | 92 |
|
|
2018
Q4 | $1.68M | Buy |
+18,212
| New | +$1.6M | 0.44% | 20 |
|
Other funds holding ABBV
Aptus Capital Advisors's ABBV Position: Q2 2026 in Review
Aptus Capital Advisors increased its AbbVie (ABBV) stake by 5.4% in Q2 2026, buying an estimated $1.57M and bringing the position to 142,030 shares worth $35.7M. The position accounts for 0.24% of the portfolio, ranked #83.
Aptus Capital Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Aptus Capital Advisors held 142,030 shares of AbbVie worth $35.7M as of Q2 2026.
- Aptus Capital Advisors bought 7,311 AbbVie shares in Q2 2026, an estimated $1.57M.
- AbbVie made up 0.24% of Aptus Capital Advisors's portfolio in Q2 2026, its #83 holding.
- Aptus Capital Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.